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Available online 5 September 2009Background: Responsiveness to cognitive behaviour therapy (CBT) in psychosis may have a
neurological basis. This study aimed to determine whether improvement in symptoms
following CBT for psychosis (CBTp) in people with schizophrenia is positively associated with
pre-therapy grey matter volume in brain regions involved in cognitive processing.
Methods: Sixty outpatients stable on medication with at least one distressing symptom of
schizophrenia and willing to receive CBTp in addition to their standard care (SC), and 25
healthy participants underwent magnetic resonance imaging. Subsequently, 30 patients
received CBTp (CBTp+SC; 25 completers) for 6–8 months and 30 continued with their
standard care (SC; 19 completers). Symptoms in all patients were assessed (blindly) at entry
and follow-up.
Results: The CBTp+SC and SC groups did not differ clinically at baseline, and only the CBTp+SC
group showed improved symptoms at follow-up. Severity of baseline symptoms was not
associated with CBTp responsiveness. Reduction with CBTp in positive symptoms was
associated with greater right cerebellum (lobule VII) grey matter volume, in negative
symptomswith left precentral gyrus and right inferior parietal lobule greymatter volumes, and
in general psychopathology with greater right superior temporal gyrus, cuneus and cerebellum
(Crus I) grey matter volumes. Grey matter volume in these brain areas did not correlate with
the severity of baseline symptoms.
Conclusion: Grey matter volume of the frontal, temporal, parietal and cerebellar areas that are
known to be involved in the co-ordination of mental activity, cognitive ﬂexibility, and verbal
learning and memory predict responsiveness to CBTp in patients with psychosis.
© 2009 Elsevier B.V. Open access under CC BY license. Keywords:
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Schizophrenia1. Introduction
A number of randomised-controlled trials have estab-
lished that cognitive-behaviour therapy (CBT) for psychosis is
efﬁcacious (Wykes et al., 2008). Efﬁcacy is clearest for
patients who are antipsychotic medication-resistant (Kuipersy, PO78, Institute o
l.: +44 207 848 0233
).
BY license. f
;et al., 1997; Tarrier et al., 1998), with acute patients not
beneﬁting as much from therapy (Garety et al., 2008). Most
studies have targeted positive symptoms of psychosis, but
beneﬁts have also been found in a number of different areas,
such as negative symptoms, depression and social function-
ing (Wykes et al., 2008). A meaningful clinical response to
CBTp, however, is seen in only about 50% of patients with
psychosis who receive it (Pfammatter et al., 2006; Wykes
et al., 2008).
Predictors of response to CBT for psychosis (CBTp) remain
unclear. In one study, cognitive ﬂexibility about delusions
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et al., 1997). CBTp requires patients with psychosis to
generate alternative explanations of their psychotic experi-
ences (Kuipers et al., 2006). Patients whose cognitive
ﬂexibility is challenged may not be able to consider new
ways of thinking or coping. It is thought that CBT operates at
the level of the cortex and explicit processing of meaning
(Gorman et al., 1989; van der Gaag, 2006). CBTp responsive-
ness thus may be inﬂuenced by the integrity of speciﬁc brain
regions that are involved in complex top-down processing of
information (Kumari, 2006; van der Gaag, 2006).
This study aimed to determine whether improvement in
symptoms following CBTp in people with psychosis when
added to their standard care (SC) is positively associated with
pre-therapy grey matter volume (GMV). A number of brain
regions are found to be structurally deﬁcient, on average, in
people with schizophrenia compared to healthy people
(Honea et al., 2005; Shenton et al., 2001) and these deﬁcits
in turn relate to impairment in a range of cognitive domains,
including cognitive ﬂexibility, in schizophrenia (Antonova
et al., 2004).
We hypothesized that greater improvement in symptoms
following CBTp+SC would be associated with greater GMV at
baseline (pre-CBTp) in the frontal lobes, given previously
reported positive associations between frontal lobe GMV and
executive functioning, including cognitive ﬂexibility, in
schizophrenia (Antonova et al., 2004). However, given the
dearth of studies on both cognitive and MRI predictors of
CBTp, we explored positive associations between GMV and
CBTp responsiveness across the whole brain. We also
explored negative associations between GMV across the
whole brain and CBTp+SC responsiveness and did not
hypothesize for GMV in any speciﬁc regions to show a
negative association.
2. Materials and methods
2.1. Participants and design
Participants were 60 outpatients with a DSM-IV diagnosis
of schizophrenia or schizoaffective disorder who were willing
to receive CBTp in addition to their usual care, and 25 healthy
participants. Of these, 30 patients received CBTp+SC (25
completers) and 30 patients received SC (19 completers). The
groups were matched on average for age, years in education
and sex (Table 1). No participant had a history of neurological
or organic illness or head injury.
Patients were recruited from the South London and
Maudsley (SLAM) NHS Foundation Trust, were on stable
doses of antipsychotic medication for at least two years and
on the current antipsychotic drug for at least three months
prior to taking part (86% on atypical antipsychotics), and had
a score of ≥60 on the Positive and Negative Syndrome Scale
(PANSS, Kay et al., 1987) and at least one persistent positive
symptom (a score of 3 or above on at least one of the positive
symptoms items of the PANSS, which they experienced as
distressing). The patients in the CBTp+SC and SC groupswere
recruited from the same geographical area, were identiﬁed by
local psychiatric consultants as suitable for CBTp, and wished
to receive CBTp in addition to their usual care. Patients who
were referred to and accepted for CBTp by the PsychologicalInterventions Clinic for Outpatients with Psychosis (PICuP),
SLAM NHS Foundation Trust went into the CBTp+SC group.
The researchers did not have a say in which of the patients
might receive CBT at this specialist clinic. With the resources
available to the SLAM NHS Foundation Trust at the time of
this investigation, only a small number (about 10%) of eligible
patients were offered CBT for psychosis. Others who matched
demographically and clinically as much as possible those
accepted for CBTp by the PICuP were studied as part of the SC
group over the same interval as the CBTp+SC group patients.
SC consisted of case management offered by the case
management team for a particular geographical area. The
team includes a dedicated care coordinator who sees the
patient on a regular basis. Six-monthly care plan assessment
reviews are carried out with a focus on recovery. There was
no change in antipsychotic dosage over the follow-up period
in either group.
The study was approved by the local ethics committee. All
participants provided written informed consent to their
participation andwere compensated for their time and travel.
2.2. Cognitive behaviour therapy
Therapy followed the procedure developed by Fowler and
colleagues (1995). Therapy was delivered weekly or fort-
nightly, as preferred by the patient, over an average of 16
individual one-hour sessions. Therapy lasted for 6–9 months,
according to NICE guidelines (NICE, 2008). It was based on
individualized formulations, and aimed to reduce distress and
interference arising from psychotic symptoms, reduce de-
pression, anxiety and hopelessness, andmodify dysfunctional
schemas when appropriate. Initial sessions focused on
facilitating engagement in therapy. The therapist endeavored
to build and maintain a good therapeutic relationship by
taking a ﬂexible approach that focused on the patient's needs
(Kuipers et al., 1997). The therapists were qualiﬁed CBT
practitioners, and were supervised by experienced clinical
psychologists (EK, EP) with expertise in CBTp.
2.3. Clinical assessments
Clinical diagnosis was conﬁrmed by the Structured Clinical
Interview for DSM-IV (First et al., 2002). PANSS assessments
(Kay et al., 1987) were performed on all patients before and
after CBTp+SC by an experienced psychiatrist (DF) who was
blind to whether or not a patient received CBTp in addition to
their usual treatment. This psychiatrist had no role in patient
recruitment or clinical management of any of the patients
included in this investigation. Appointments for these
assessments were made by another member of the research
team.We have no evidence that blindness was broken during
these assessments.
2.4. Magnetic resonance imaging acquisition
All participants underwent structural magnetic resonance
imaging (MRI) at baseline. MRI scans were acquired using a
1.5 Tesla GE NV/i Signa system (General Electric, Milwaukee
WI, USA) at the Maudsley Hospital, London. Initially, a series
of sagittal fast gradient echo scout images were acquired. A
3-D inversion recovery prepared fast spoiled GRASS sequence
Table 1
Demographic and clinical characteristics of study groups.
Characteristic CBTp+SC patients
(n=25)
SC patients
(n=19)
Healthy
participants
(n=25)
Model χ2 (df) p
Sex: male/female (n) 17/8 15/4 17/8 Group 0.80 (2) 0.672
F (df)
Age in years−mean, s.d. 35.6, 8.1 40.6, 9.8 33.7, 12.6 Group 2.48 (2,66) 0.090
Years in education−mean, s.d. 13.9, 3.1 13.5, 1.6 15.1, 2.5 Group 2.53 (2,66) 0.093
Diagnosis Schizophrenia/schizoaffective disorder 24/1 17/2 – Group 0.72 (1,44) 0.395
Duration of illness a, years−mean, s.d. 11.1, 7.9 15.2, 11.5 – Group 1.94 (1,42) 0.170
Age at illness onset, years−mean, s.d. 24.4, 8.0 25.4, 8.2 – Group 0.16 (1,42) 0.691
Symptoms (PANSS b)−mean, s.d. Baseline Follow-up Baseline Follow-up
Positive 18.1, 4.8 ▼14.8, 4.2 18.4, 3.4 18.0, 3.8 – Time×Group 5.84 (1,42) 0.024
Negative 17.9, 4.4 ▼15.5, 4.2 19.2, 3.9 20.1, 4.6 – Time×Group 6.67 (1,42) 0.016
General psychopathology 33.2, 7.2 ▼28.3, 7.2 34.6, 4.6 34.3, 6.9 – Time×Group 4.37 (1,42) 0.042
Total 69.1, 13.6 ▼58.6, 14.5 72.2, 9.0 72.3, 13.1 – Time×Group 7.93 (1,42) 0.007
Medication level c−mean dose, s.d. 520.7, 380.7 484.7, 345.0 – Group 0.11 (2,66) 0.748
Total grey matter volume (ml)−mean, s.d. 702.4, 72.0 697.5, 68.4 736.4, 72.5 Group 2.08 (2,66) 0.133
Total white matter volume (ml)−mean, s.d. 410.1, 47.5 415.3, 41.7 417.8, 48.9 Group 0.18 (2,66) 0.838
Total cerebro-spinal ﬂuid (ml)−mean, s.d. 525.6, 87.2 527.9, 61.5 531.0, 82.7 Group 0.03 (2,66) 0.971
▼Lower symptom scores (p<0.01) at follow-up in the CBTp+SC, but not in the SC, group.
a Difference between the age at onset of psychotic symptoms (as reported by the patient and, where possible, conﬁrmedwith clinical records and other sources)
and current age.
b PANSS: Positive and Negative Syndrome Scale.
c Medication level expressed in chlorpromazine equivalents.
148 P. Premkumar et al. / Schizophrenia Research 115 (2009) 146–155was applied to the whole brain to obtain T1-weighted
images in the axial plane with 1.5 mm contiguous sections
(TR=18 ms, TI=450 ms, TE=5.1 ms, ﬂip angle=20° with
one data average and a 256×256×128 voxel matrix).
Acquisition parameters were chosen using a sophisticated
image contrast simulation (Simmons et al., 1996).
2.5. MRI pre-processing
Structural images were converted into ANALYZE format
(ANALYZE software, BRU, Mayo Foundation, Rochester, MN)
and pre-processed using Statistical Parametric Mapping
(SPM2; http://www.ﬁl.ion.ucl.ac.uk/spm), running in
MATLAB 2006a (MathWorks, Natick, MA) as previously
described (Premkumar et al., 2008). Customised T1-weighted
templates of the whole brain, grey matter, white matter and
cerebro-spinal ﬂuid (CSF) were created for patient and
healthy participant groups separately, and also for the
whole study sample (patients and healthy participants
combined). For analyses concerning GMV correlates of
symptom improvement in the CBTp+SC group, templates
used were derived from the patient group alone. For
comparisons between CBTp+SC responders, CBTp+SC non-
responders and healthy participant groups, templates created
for the whole study sample were utilized. Using a separate
‘patients only’ template for the analyses concerning GMV
correlates of CBTp+SC allowed us to determine CBTp speciﬁc
effects, without confounding for GMV-averaged effects of
healthy participants.
2.6. Statistical analysis
2.6.1. Baseline demographic and clinical characteristics and
total brain volumes
Analyses of variance (ANOVA) were performed to exam-
ine baseline group differences (as applicable) in age, years ineducation, age of illness onset, duration of illness and
medication. Gender distribution was examined using chi-
square test.
The total grey matter, white matter and CSF volumes for
each individual were calculated from the unsmoothed
modulated segmented images using SPM2 and the values
representing the volume in milliliters extracted. Intracranial
volume was calculated as the sum of the grey matter, white
matter and CSF volumes. Group differences in total grey
matter, white matter and CSF volumes were examined in
SPSS (v15) by means of ANOVA.
2.6.2. Symptom change following CBTp
Repeated-measures ANOVAs were performed to deter-
mine symptom change from baseline to follow-up, with time
(baseline, follow-up) as the within-subject factor and group
(CBTp+SC and SC) as the between-subjects factor. Following
signiﬁcant symptom improvement at follow-up in the CBTp+
SC group but not the SC group (see Results section), potential
associations between symptom improvement and age,
duration of illness, medication dosage (chlorpromazine
equivalents) and baseline symptoms (total PANSS; positive,
negative and general psychopathology subscale scores) were
examined in the CBTp+SC group using Pearson's r. Such
analyses were not performed in the SC group since this group
did not show clinical change between the baseline and
follow-up.
2.6.3. MRI correlates of symptom change following CBTp
Analyses of GMV correlates of CBTp responsiveness were
performed in SPM5 (5–1782). For the purpose of this analysis,
treatment outcome in the CBTp+SC group, was estimated as
the residual change in PANSS symptoms (Siegle et al., 2006).
To examine the associations between baseline (pre-CBTp)
GMV and symptom improvement in the CBTp+SC group,
residual symptom change scores on the PANSS (total and
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whole brain. The resultant SPM correlation maps were
thresholded at p<0.005 uncorrected. Given the exploratory
nature of this study and the suggestion that the procedure for
correction for multiple comparisons in SPM (originally
designed for the analysis of functional data) is overly strict
when applied to structural data (Sowell et al., 1999),
relationships between CBTp+SC responsiveness and brain
regional volumes where clusters were larger than 300 voxels
with a local maxima reaching T>2.81 (p<0.005) were
treated as being of interest and a small volume correction
(SVC; 10 mm radius sphere centred on the maxima voxel)
was applied to determine whether a cluster is signiﬁcant
(p=0.05, family-wise error corrected) after correcting for
multiple comparisons within a locally deﬁned volume.
We then extracted the values representing the percentage
of total grey/white matter volume under a smoothing kernel
relative to the total grey/white matter volume for each
participant in the patient group at the maxima voxels of all
the regions where GM volumes were associated with
symptom change and/or baseline symptoms in the CBTp+
SC group. Partial correlations were performed between these
values and symptom change controlling for intracranial
volume. To determine whether these associations might
also be present in the SC group, the GM intensities at each
signiﬁcant voxel were also extracted for the SC group and
correlations performed between these values and symptom
change. Finally, scatterplots were used to explore whether
GMV correlates of symptom improvement in CBTp+SC
patients receiving clozapine (n=6) differed from those
receiving other types of antipsychotics.
2.6.4. Group differences in regional brain volumes
Group differences in GMV were also examined in SPM5
(5–1782). We compared regional GMVs across the whole
brain of CBTp+SC responders (patients who showed a 20%
improvement from baseline on PANSS total symptoms) with
that of CBTp+SC non-responders and healthy participants
using independent sample t-tests and applied the sameTable 2
GMV correlates (positive associations) of symptom improvement following CBTp (n
corrected p<0.05).
Brain region Side BA a MNI b coordinates
x y Z
PANSS positive symptoms improvement
Cerebellum (lobule VII) Right 39 −52 −59
PANSS negative symptoms improvement
Precentral gyrus Left 6 −50 −8 37
Inferior parietal lobule Right 40 58 −34 24
PANSS general psychopathology improvement
Superior temporal gyrus Right 22 61 −34 8
Cuneus Right 17 14 −71 9
Cerebellum (Crus I) Right 45 −41 −36
PANSS total symptoms improvement
Cuneus Right 17 16 −71 9
Superior temporal gyrus Right 22 60 −33 13
a Broadmann area.
b Montreal Neurological Institute.signiﬁcance criteria as noted earlier for association with
responsiveness to CBTp. Following the observation of group
differences in hippocampal GMV, group differences were re-
evaluated using masks for left and right hippocampus from
the PickAtlas software (Maldjian et al., 2003).
3. Results
3.1. Baseline demographic and clinical characteristics and total
brain volumes
The demographic and clinical characteristics and total grey
matter, white matter and CSF volumes of the patients and
healthy participants are presented in Table 1. The CBTp+SC
and SC patient groups did not differ in demographic
characteristics, symptoms,medication level, or brain variables
at baseline.
3.2. Symptom change following CBTp
Symptom severity in the CBTp+SC group was reduced at
follow-up relative to the SC group (Table 1). CBTp+SC patients
showed an improvement, on average, of 14.5% (s.d.=16.9%) on
PANSS total symptoms following CBTp+SC, while SC patients
showed no change. Post-CBTp improvement in symptoms was
not associated signiﬁcantly with any baseline clinical
characteristic.
3.3. MRI correlates of symptom improvement following CBTp
In the CBTp+SC group, greater GMV in the right
cerebellum was associated with improvement in positive
symptoms (Table 2 and Fig. 1). Greater GMV in the left
precentral gyrus and right inferior parietal lobule was
associated with improvement in negative symptoms. Greater
GMV in the right STG, cuneus and cerebellum was associated
with improvement in general psychopathology. Greater GMV
in the right cuneus and right STG was positively associated
with improvement in total symptoms. These associations in=25) (height threshold p=0.005 for all voxels; T>2.81; family-wise error
Voxel T value Number of contiguous voxels Voxel equiv Z
3.21 313 2.89
3.75 1244 3.29
3.72 1100 3.26
3.8 1747 3.31
3.86 708 3.35
3.83 955 3.33
3.44 319 3.06
3.57 1662 3.15
Fig. 1. Grey matter areas (maps thresholded at p=0.005 uncorrected) showing a positive association with symptom improvement following CBTp in patients.
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intracranial volume, and were not found in the SC group
(Table 3). There were no negative associations between GMV
in any brain areas and symptom improvement.
The GMV correlates of post-CBTp symptom improvement
appeared to be similarly present in patients receiving
clozapine and those receiving other antipsychotics (Fig. 2).Table 3
Correlations between localized GMVs (with positive associations with CBTp respon
Brain region-symptom improvement correlate CBTp+SC
r (p)
Right cerebellum-positive symptoms 0.557 (0.004)
Left precentral gyrus-negative symptoms 0.615 (0.001)
Right inferior parietal lobule-negative symptoms 0.613 (0.001)
Right superior temporal gyrus-general psychopathology 0.621 (0.001)
Right cuneus-general psychopathology 0.627 (0.001)
Right cerebellum-general psychopathology 0.435 (0.030)
Right cuneus-total symptoms 0.583 (0.002)
Right superior temporal gyrus-total symptoms 0.597 (0.002)3.4. Group differences in regional brain volumes
CBTp+SC responders (n=11) had greater left and right
hippocampal volumes relative to healthy participants and
greater left hippocampal volumes relative to CBTp+SC non-
responders (Table 4 and Fig. 3). No other group differences
met the signiﬁcance criteria.se within SPM5) and symptom improvement in CBTp+SC and SC groups.
CBTp+SC controlling for intracranial volume SC
Partial r (p) r (p)
0.581 (0.003) 0.421 (0.073)
0.653 (0.001) −0.315 (0.189)
0.628 (0.001) 0.002 (0.994)
0.676 (<0.001) −0.264 (0.275)
0.700 (<0.001) 0.216 (0.375)
0.627 (0.001) 0.226 (0.352)
0.618 (0.001) 0.267 (0.270)
0.654 (0.007) −0.288 (0.232)
Fig. 2. Scatter plots showing the relationship between the percentage greymatter volumes (relative to groupmean) at the maxima voxel of all the regions (y-axis)
showing an association with symptom change (x-axis) for CBTp+SC patients receiving clozapine or other antipsychotics.
151P. Premkumar et al. / Schizophrenia Research 115 (2009) 146–1554. Discussion
This study examined structural MRI predictors of symp-
tom change following CBTp in patients with psychosis and
found that the patients who received CBTp added to their
usual care (SC), on average, showed improved symptoms at
follow-up; SC patients showed the same level of symptoms atstudy entry and follow-up. In the CBTp+SC group, greater
symptom improvement was associated with greater GMV as
follows: (a) positive symptoms with right cerebellum (lobule
VII), (b) negative symptoms with left precentral gyrus and
right inferior parietal lobule, (c) general psychopathology
with right STG, right cuneus and right cerebellum (Crus I),
and (d) total symptoms with right STG and right cuneus.
Table 4
Differences in the posterior hippocampus GMVs between CBTp+SC
responders (n=11), CBTp+SC non-responders (n=14) and healthy
participants (n=25) (height threshold p=0.005, cluster size >10 voxels).
Side MNI a coordinates Voxel
T value
Number of
contiguous
voxels
Voxel
equiv Z
x y z
CBTp+SC responders>healthy participants
Right 28 −28 −5 3.33 132 3.07
Left −25 −30 −5 4.36 797 3.86
CBTp+SC responders>CBTp+SC non-responders
Left −27 −36 −5 2.89 11 2.64
a Montreal Neurological Institute.
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responders (n=11/25) had greater posterior hippocampal
volume bilaterally relative to healthy participants and greater
left posterior hippocampal volume than CBTp+SC non-
responders.
4.1. MRI correlates of symptom improvement following CBTp
Contrary to our expectation, no signiﬁcant association was
found between CBTp responsiveness and prefrontal GMV.
However, GMVs in a number of other regions as discussed
below were positively associated with CBTp responsiveness.
We found that greater GMV in the right cerebellum
(lobule VII and Crus I) was associated with improvement in
positive symptoms and general psychopathology. Although
the cerebellum, traditionally, has been implicated in motor
control, recent data demonstrate cerebellar contributions to
higher order cognitive functions, especially the task manage-
ment and multi-tasking components of executive processingFig. 3. Greater posterior hippocampal volume (maps thresholded at p=0.05 uncorr
non-responders.(Andreasen and Pierson, 2008), manipulation of information
held in verbal working memory [in a manner similar to that
observed for the prefrontal cortex (Hayter et al., 2007)] and
co-ordination of mental activity (Thach, 2007), all of which
are likely to be pertinent to effective CBTp. Patients with
greater cerebellar GMVs may have been more capable of
reasoning and relational processing (pooling together and
comparing decision-relevant information) and beneﬁted
most from CBT. According to Andreasen and colleagues
(Andreasen et al., 1999; Andreasen and Pierson, 2008),
disruption in the cortico-cerebellar-thalamo-cortical circuitry
results in deﬁcient processing, prioritising, retrieval, coordi-
nation, and responding to information in schizophrenia. It is
likely that functions of this circuitry are also relevant to CBTp
responsiveness in schizophrenia as suggested previously
(Kumari et al., 2009).
GMVs in the left precentral gyrus (BA6) and right inferior
parietal lobule (BA40) were positively associated with
improvement in negative symptoms. The precentral gyrus
responds when information must be continuously updated
and memory for temporal order maintained in working
memory (Wager and Smith, 2003), while the parietal lobe is
involved in both working and episodic memory (Olson and
Berryhill, 2009). Functional imaging studies also reveal
inferior parietal lobule involvement in sensory integration,
body image, concept of self, and executive function in
schizophrenia (Torrey, 2007). The association between larger
fronto-parietal GMV and greater responsiveness to CBTp in
this study could be mediated by the cognitive functions
associated with these brain regions.
Greater GMV in the right cuneus (BA17) was associated
with post-CBTp improvement in overall symptoms and gen-
eral psychopathology. The cuneus is also part of the cortico-
cerebellar-thalamic-cortical circuit proposed (mentioned ear-ected) in CBTp+SC responders relative to healthy participants and CBTp+SC
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of cognitive dysmetria in schizophrenia and shows activity
changes during recall of practiced verbal material (Crespo-
Facorro et al., 1999). Greater availability of cuneal GMV in
patients may beneﬁt better recall of discussions during
therapy and in turn their ability to carry out home
assignments.
Greater GMV in the right posterior STG was associated
with CBTp-led improvement in total symptoms and general
psychopathology. Greater bilateral posterior STG GMV has
been associated with better abstraction (Nestor et al., 1993),
and right posterior STG with fewer perseverative errors on
the Wisconsin Card Sorting test (Nestor et al., 2007b) and
good insight in schizophrenia (Cooke et al., 2008). Greater
right posterior STG GMV thus may enable better cognitive
ﬂexibility and insight into their symptoms, and in turn
facilitate CBTp responsiveness.
It is important to highlight that GMV alterations in certain
brain areas in schizophrenia are associated with both low
level of certain cognitive functions (Antonova et al., 2004)
and severity of symptoms (review, Kumari and Cooke, 2006).
We chose to consider the GMV correlates of CBTp respon-
siveness in terms of their neuropsychological signiﬁcance
because (a) there is no evidence to our knowledge (from any
previous study or this study) that baseline symptom severity
moderates the effects of CBT for psychosis, and (b) the GMVs
associated with CBTp-led improvement were also not
associated with baseline symptoms in this study. Further-
more, for the purpose of detecting relationships between pre-
therapy GMVs and CBTp-led improvement, CBTp responsive-
ness was deﬁned as residual change scores (estimated from
baseline symptom severity-predicted change scores) follow-
ing the methods proposed for such studies by Siegle and
colleagues (2006). Although at present there are very limited
data on predictors of CBTp in schizophrenia, studies in other
psychiatric disorders, such as depression and anxiety, have
highlighted the importance of pretherapy level of cognitive
functions as moderators of responsiveness to CBT (Julian and
Mohr, 2006; Mohlman and Gorman, 2005) and this may be
even more salient in patients with schizophrenia who, on
average, show deﬁcient performance across a range of
neuropsychological tasks (Reichenberg and Harvey, 2007).
4.2. Group differences in hippocampal volume
CBTp+SC responders showed greater posterior hippo-
campal volume compared to healthy participants and CBTp+
SC non-responders. The hippocampal volume is positively
associated with verbal learning and memory in psychosis
(Antonova et al., 2004; Nestor et al., 2007a; Rametti et al.,
2007). Although hippocampal volume is generally smaller in
patients with schizophrenia (Honea et al., 2005; Shenton
et al., 2001), a recent study (Thoma et al., 2009) reported
smaller anterior, but not posterior, hippocampal volumes in
schizophrenia patients, compared to controls; this study
further showed that the anterior hippocampal volume
correlated negatively, while the posterior hippocampal
volume correlated positively, with memory measures in the
schizophrenia group. Based on these previous ﬁndings, it can
be suggested that greater posterior hippocampal volume
facilitated memory for verbal materials and thus wasconducive for treatment response in CBTp+SC responders.
In a recent study, MacQueen and colleagues (2008) found
greater bilateral hippocampal volume at baseline in patients
with major depression who remitted, compared to those who
did not remit, after 8-weeks antidepressant therapy (Mac-
Queen et al., 2008). They suggested that greater hippocampal
volume may afford better cognitive (Leal-Galicia et al., 2008;
Wais, 2008) and emotion processing (Dolcos et al., 2005;
LaBar and Cabeza, 2006; Phelps, 2004; Viveros et al., 2007) in
psychiatric patients and enable them to reformulate their
experiences (symptoms) resulting in improved symptoms
following treatment. It is also possible that CBTp responders
of our study had other characteristics that were not measured
but may be associated with both greater-than-normal
posterior hippocampal GMVs and a beneﬁcial response to
CBTp. For example, the right hippocampus is also enlarged in
people who meditate (Holzel et al., 2008; Luders et al., 2009).
However, we had not expected to ﬁnd a greater-than-normal
posterior hippocampal GMV in CBTp responders; this ﬁnding
needs to be replicated before being taken seriously.
4.3. Limitations
A limitation of the study is that although some speciﬁc
predictions were made about the neural networks associated
with symptomchange in response toCBTp+SC, the analysiswas
exploratory in nature as this is the ﬁrst study to our knowledge
to examine the brain structural predictors of CBTp+SC and
our ﬁndings are based on a small sample. It is possible that the
GMV correlates of CBTp responsiveness were confounded by
antipsychotic drug treatment. We, however, did not ﬁnd any
differences in the distribution of GMV correlates between
patients receiving clozapine (n=6) and patients receiving
other antipsychotic drugs. We were not able to determine the
effect of mood stabilizers on the GMV-symptom improvement
associations due to the small number of CBTp+SC patients
on mood stabilizers (n=4). Finally, in the absence of pre-CBTp
assessment of relevant cognitive functions, the proposed
neuropsychological signiﬁcance of MRI predictors of CBTp
remains speculative.
4.4. Conclusions
In conclusion, greater GMV of the brain areas that sub-
serve the co-ordination of mental activity, cognitive ﬂexibil-
ity, and verbal learning and memory may predict a beneﬁcial
response to CBTp in patients with psychosis. These ﬁndings
need to be replicated in relatively larger samples and
supplemented with pre-CBTp assessment of relevant cogni-
tive functions using sophisticated neuropsychological tests
along with MRI to conﬁrm the neuropsychological signiﬁ-
cance of MRI predictors in a direct manner.
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